Literature DB >> 27196588

Comparing CT colonography and flexible sigmoidoscopy: a randomised trial within a population-based screening programme.

Daniele Regge1, Gabriella Iussich2, Nereo Segnan3, Loredana Correale4,5, Cesare Hassan6, Arrigo Arrigoni7, Roberto Asnaghi8, Piero Bestagini9, Gianmarco Bulighin10, Maria Carla Cassinis11, Andrea Ederle10, Andrea Ferraris11, Giovanni Galatola1, Teresa Gallo12, Giovanni Gandini11, Licia Garretti13, Maria Cristina Martina11, Daniela Molinar14, Stefania Montemezzi15, Lia Morra4,5, Massimiliano Motton15, Pietro Occhipinti16, Lucia Pinali15, Gian Alberto Soardi15, Carlo Senore3.   

Abstract

IMPORTANCE AND AIMS: The role of CT colonography (CTC) as a colorectal cancer (CRC) screening test is uncertain. The aim of our trial was to compare participation and detection rate (DR) with sigmoidoscopy (flexible sigmoidoscopy (FS)) and CTC in a screening setting. DESIGN SETTING AND PARTICIPANTS: We conducted two randomised clinical trials (RCTs). (1) Participation RCT: individuals, aged 58 years, living in Turin (Italy), were randomly assigned to be invited to FS or CTC screening; (2) detection RCT: residents in northern Italy, aged 58-60, giving their consent to recruitment, were randomly allocated to CTC or FS. Polyps ≥6 mm at CTC, or 'high-risk' distal lesions at FS, were referred for colonoscopy (TC). MAIN OUTCOME MEASURES: Participation rate (proportion of invitees examined); DR of advanced adenomas or CRC (advanced neoplasia (AN)).
RESULTS: Participation was 30.4% (298/980) for CTC and 27.4% (267/976) for FS (relative risk (RR) 1.1; 95% CI 0.98 to 1.29). Among men, participation was higher with CTC than with FS (34.1% vs 26.5%, p=0.011). In the detection RCT, 2673 subjects had FS and 2595 had CTC: the AN DR was 4.8% (127/2673, including 9 CRCs) with FS and 5.1% (133/2595, including 10 CRCs) with CTC (RR 1.08; 95% CI 0.85 to 1.37). Distal AN DR was 3.9% (109/2673) with FS and 2.9% (76/2595) with CTC (RR 0.72; 95% CI 0.54 to 0.96); proximal AN DR was 1.2% (34/2595) for FS vs 2.7% (69/2595) for CTC (RR 2.06; 95% CI 1.37 to 3.10). CONCLUSIONS AND RELEVANCE: Participation and DR for FS and CTC were comparable. AN DR was twice as high in the proximal colon and lower in the distal colon with CTC than with FS. Men were more likely to participate in CTC screening. TRIAL REGISTRATION NUMBER: NCT01739608; Pre-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COLONIC NEOPLASMS; COLORECTAL CANCER SCREENING

Mesh:

Year:  2016        PMID: 27196588     DOI: 10.1136/gutjnl-2015-311278

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial.

Authors:  Lapo Sali; Leonardo Ventura; Grazia Grazzini; Alessandra Borgheresi; Silvia Delsanto; Massimo Falchini; Beatrice Mallardi; Paola Mantellini; Stefano Milani; Stefano Pallanti; Marco Zappa; Mario Mascalchi
Journal:  Eur Radiol       Date:  2018-11-06       Impact factor: 5.315

Review 2.  CT colonography: role in FOBT-based screening programs for colorectal cancer.

Authors:  Lapo Sali; Grazia Grazzini; Mario Mascalchi
Journal:  Clin J Gastroenterol       Date:  2017-04-26

3.  Bowel preparation in CT colonography: Is diet restriction necessary? A randomised trial (DIETSAN).

Authors:  Davide Bellini; Domenico De Santis; Damiano Caruso; Marco Rengo; Riccardo Ferrari; Tommaso Biondi; Andrea Laghi
Journal:  Eur Radiol       Date:  2017-08-10       Impact factor: 5.315

Review 4.  Review of radiological screening programmes for breast, lung and pancreatic malignancy.

Authors:  Helena Barton; David Shatti; Charlotte Anne Jones; Mathuri Sakthithasan; Will W Loughborough
Journal:  Quant Imaging Med Surg       Date:  2018-06

Review 5.  CT colonography for population screening of colorectal cancer: hints from European trials.

Authors:  Lapo Sali; Daniele Regge
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

6.  [Colorectal cancer: role of imaging in screening].

Authors:  T Mang
Journal:  Radiologe       Date:  2019-01       Impact factor: 0.635

7.  High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.

Authors:  Lisanne S Rigter; Manon C W Spaander; Berthe M P Aleman; Tanya M Bisseling; Leon M Moons; Annemieke Cats; Pieternella J Lugtenburg; Cecile P M Janus; Eefke J Petersen; Judith M Roesink; Richard W M van der Maazen; Petur Snaebjornsson; Ernst J Kuipers; Marco J Bruno; Evelien Dekker; Gerrit A Meijer; Jan Paul de Boer; Flora E van Leeuwen; Monique E van Leerdam
Journal:  Cancer       Date:  2018-12-18       Impact factor: 6.860

Review 8.  Optimal Strategies for Colorectal Cancer Screening.

Authors:  Shailavi Jain; Jetrina Maque; Artin Galoosian; Antonia Osuna-Garcia; Folasade P May
Journal:  Curr Treat Options Oncol       Date:  2022-03-22

Review 9.  How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: A minireview.

Authors:  Alessandro Fancellu; Simone Veneroni; Antonio Santoru; Arianna Meloni; Valeria Sanna; Giorgio C Ginesu; Giulia Deiana; Panagiotis Paliogiannis; Chiara Ninniri; Teresa Perra; Alberto Porcu
Journal:  World J Gastrointest Oncol       Date:  2022-08-15

Review 10.  Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline - Update 2020.

Authors:  Cristiano Spada; Cesare Hassan; Davide Bellini; David Burling; Giovanni Cappello; Cristina Carretero; Evelien Dekker; Rami Eliakim; Margriet de Haan; Michal F Kaminski; Anastasios Koulaouzidis; Andrea Laghi; Philippe Lefere; Thomas Mang; Sebastian Manuel Milluzzo; Martina Morrin; Deirdre McNamara; Emanuele Neri; Silvia Pecere; Mathieu Pioche; Andrew Plumb; Emanuele Rondonotti; Manon Cw Spaander; Stuart Taylor; Ignacio Fernandez-Urien; Jeanin E van Hooft; Jaap Stoker; Daniele Regge
Journal:  Eur Radiol       Date:  2021-05       Impact factor: 5.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.